Loading
companiesCompany
Bellicum Pharmaceuticals
Bellicum was a Houston cell-therapy company known for its rimiducid safety switch, which let doctors switch off infused T cells; its lead product for transplant failed to reach approval and the company wound down.
Also called: Bellicum Pharmaceuticals, Inc.Bellicum
Overview
Bellicum Pharmaceuticals, founded in 2004 in Houston, built cell therapies around an inducible caspase-9 safety switch triggered by the small molecule rimiducid. Its lead product rivogenlecleucel (BPX-501), donor T cells given after haploidentical stem cell transplant in children, reached phase 3 in Europe, and later GoCAR-T products entered early trials before the company ceased operations in 2023. Its trials remain on ClinicalTrials.gov under Bellicum as lead sponsor.
Similar pages
- CompanyVor Biopharma
Shares Allogeneic stem cell transplantation, Pivotal (registrational) trial, Clinical trial, CAR-T cell therapy.
- CompanyVion Pharmaceuticals
Shares Pivotal (registrational) trial, Clinical trial, Acute myeloid leukaemia.
- CompanyCyclacel Pharmaceuticals
Shares Pivotal (registrational) trial, Clinical trial, Acute myeloid leukaemia.
- PersonJohn F. DiPersio
Shares Allogeneic stem cell transplantation, CAR-T cell therapy, Acute lymphoblastic leukaemia, Acute myeloid leukaemia.
- CompanyJW Pharmaceutical
Shares Pivotal (registrational) trial, Clinical trial, Acute myeloid leukaemia.
- CompanySunesis Pharmaceuticals
Shares Pivotal (registrational) trial, Clinical trial, Acute myeloid leukaemia.
- CompanyCartesian Therapeutics
Shares Pivotal (registrational) trial, Clinical trial, CAR-T cell therapy.
- TargetCD7
Shares Allogeneic stem cell transplantation, CAR-T cell therapy, Acute lymphoblastic leukaemia, Acute myeloid leukaemia.